Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: a position paper of the MeetURO Group.
Future Oncol
; 15(22): 2657-2666, 2019 Aug.
Article
en En
| MEDLINE
| ID: mdl-31339065
ABSTRACT
Tyrosine kinase inhibitors still play a very important role in the treatment of metastatic renal cell carcinoma despite a continuously changing scenario, in which immunotherapy and several combination-based approaches are also available. In this light, patient-reported outcomes and health-related quality of life are important factors in the selection of the best first-line treatment. This Review focuses on the existing evidence on patient-reported outcomes and health-related quality of life with several tyrosine kinase inhibitors (pazopanib, sunitinib, cabozantinib and tivozanib) used as first-line treatment for metastatic renal cell carcinoma.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Carcinoma de Células Renales
/
Inhibidores de Proteínas Quinasas
/
Neoplasias Renales
Límite:
Humans
Idioma:
En
Revista:
Future Oncol
Año:
2019
Tipo del documento:
Article
País de afiliación:
Italia